Share this

Charnwood Molecular recently congratulated NFlection Therapeutics on the initiation of the first clinical trial of NFlection’s lead product, NFX-179 Gel, a topically applied therapy for the mitigation of Cutaneous Neurofibromatosis Type-1.

During a highly successful research collaboration over 18 months, Charnwood’s discovery group support for NFlection‘s program aided in the identification of NFX-179, with Charnwood’s development chemistry team providing a rapid delivery of the first scale-up batches of API for non-clinical studies and the confirmation of a robust and efficient synthetic route to support clinical manufacture. Working closely with the Nflection team, this led to a seamless technology transfer to a cGMP facility where multi-kilo batches were prepared.

Prof. Steve Allin, CEO and Founder of Charnwood Molecular, said “Charnwood prides itself on its ability to provide world-class scientific teams, the internal research environment and the scientific leadership required to deliver the discovery requirements of its clients. Our hugely successful collaboration with NFlection Therapeutics, and with their scientific co-founder and current advisor, John Kincaid, demonstrates what can be achieved when innovation, research excellence and collaboration form the basis of CRO-Client relationships. We congratulate the NFlection team on this significant milestone for them, and we are proud to have played a role in bringing NFX-179 closer to the clinic for this unmet medical need.”